Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis.
Zachary A. Yochum, Toni K. Choueiri(Harvard University), Connor Wells(Queen Mary University of London), Renée Maria Saliby(Yale University), Rana R. McKay(University of California San Diego), José Manuel Ruiz-Morales(Hospital Médica Sur), Kosuke Takemura(Japanese Foundation For Cancer Research), Wanling Xie(Dana-Farber Cancer Institute), Sumanta Kumar Pal(City of Hope), Thomas Powles(Queen Mary University of London), Lori Wood(Dalhousie University), Cristina Suárez(Complejo Hospitalario de Salamanca), Hedyeh Ebrahimi(City of Hope), Guillermo de Velasco(Dana-Farber Cancer Institute), Evan Ferrier, Neeraj Agarwal(University of Utah), Martín Zarbá(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Aly‐Khan A. Lalani(Juravinski Cancer Centre)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k